THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST. Date Request Received: 03 August 2015 FOI Ref: 947

Transcription

1 FREEDOM OF INFORMATION ACT 2000 THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST Date Request Received: 03 August 2015 FOI Ref: 947 Requested Information For the Royal Cornwall Hospitals NHS Trust (RCHT), please advise: 1) How many patients have been treated for metastatic castration resistant prostate cancer (mcrpc) in the last 6 weeks? a) In the last 6 weeks, please advise the quantities of enzalutamide that have been prescribed/dispensed? b) In the last 6 weeks, please advise the quantities of abiraterone that have been prescribed/dispensed? c) In the last 12 months, please advise the quantities of docetaxel that have been prescribed/dispensed? 2) How many patients have been treated for breast cancer in the past 6 months? a) In the last 6 months, please advise the quantities of the following drugs that have been prescribed/dispensed? Dasatinib Denosumab Everolimus Lapatininb Pertuzumab Trastuzumab Trastuzumab Emtansine 3) How many patients with Advanced [Stage 4] Melanoma have been treated in the past 6 months? a) In the last 6 months, please advise the quantities of the following drugs that have been prescribed/dispensed? Bevacizumab Dabrafenib Dacarbazine Ipilimumab Nivolumab Paclitaxel Pembrolizumab Trametenib Vemurafenib I understand that you are unable to confirm if the quantities of drugs prescribed/dispensed have been used to treat the conditions listed above I accept that there is no direct correlation. Julie Hughes, FOI Officer Version No. v1 Review Due: 2025 Page 1 of 2

2 Response 1) This information is not held electronically. It may be possible to determine what is being asked by completing a manual trawl of individual patient records; however, I have estimated that it would exceed the appropriate limit 1 to do so. a) Please see Appendix 1 b) Nil c) Please see Appendix 1 2) There were 226 new patients treated for breast cancer in the past 6 months. a) Please see Appendix 1 (please note Nil responses for Everolimus and Lapatininb). 3) There were 12 new patients treated for advanced (stage 4) melanoma in the past 6 months. a) Please see Appendix 1 (please note Nil response for Trametenib) Attachment(s)? Appendix 1 Prescriptions Issued 6 Weeks, 6 Months, and 12 Months Date Response Sent: 20 August The appropriate limit is specified in regulations and for RCHT this is set at 450. This represents the estimated cost of 1 person spending 2½ working days in determining whether RCHT hold the information, locating, retrieving and extracting the information. Consequently RCHT is not obliged under Section 12 of the Freedom of Information Act 2000 to respond to this part of your request. Page 2 of 2

3 FOI Ref 947 Appendix 1 Prescriptions Issued for Listed Drugs between 19 June 2015 and 31 July 2015 Drug Description Form Total Unit ENZALUTAMIDE (ENZAMET TRIAL) 40 mg Capsules Capsules 720 Capsule ENZALUTAMIDE (OPEN LABEL)(MDV TRIAL) 40 mg Capsules Capsules 496 Capsule ENZALUTAMIDE / PLACEBO (MDV TRIAL) 40 mg Capsules Capsules 248 Capsule

4 Prescriptions Issued for Listed Drugs between 01 Febuary 2015 and 31 July 2015 Drug Description Form Total Unit BEVACIZUMAB 1.25 mg in 0.05mL Pre-filled Syringe Pre-filled Syringe 13 Pre-filled Syringe BEVACIZUMAB 100 mg Infusion Infusion 261 Vial BEVACIZUMAB 400 mg Infusion Infusion mg BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 1000 mg Intravenous Infusion Intravenous Infusion 7500 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 300 mg Intravenous Infusion Intravenous Infusion 400 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 350 mg Intravenous Infusion Intravenous Infusion 500 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 400 mg Intravenous Infusion Intravenous Infusion 100 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 500 mg Intravenous Infusion Intravenous Infusion 850 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 550 mg Intravenous Infusion Intravenous Infusion 2000 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 600 mg Intravenous Infusion Intravenous Infusion 4750 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 650 mg Intravenous Infusion Intravenous Infusion 3250 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 700 mg Intravenous Infusion Intravenous Infusion 2500 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 750 mg Intravenous Infusion Intravenous Infusion 500 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 800 mg Intravenous Infusion Intravenous Infusion 3000 ml BEVACIZUMAB IN SODIUM CHLORIDE 0.9% 900 mg Intravenous Infusion Intravenous Infusion 2750 ml DABRAFENIB 50 mg Capsules Capsules 256 Capsule DACARBAZINE 1 g Injection Injection 40 Vial DASATINIB (SPIRIT 2 TRIAL) 50 mg Tablets Tablets 450 Tablet DENOSUMAB (120MG/1.7ML) 70 mg in 1mL Injection Injection ml DENOSUMAB / PLACEBO (AMGEN - D CARE TRIAL) 70 mg/ml Injection Injection 12 Kit DENOSUMAB 60 mg in 1mL Injection Injection 32 Pre-filled Syringe IPILIMUMAB 5 mg in 1mL Injection Injection 1740 ml NIVOLUMAB (CA209) 100 mg in 10mL Injection Injection 120 ml NIVOLUMAB (CA TRIAL) 100 mg in 10mL Injection Injection 32 Vial PACLITAXEL 6 mg in 1mL Injection Injection ml PACLITAXEL ALBUMIN (SIEGE TRIAL) 5 mg in 1mL Injection Injection 11 x 100mg Vial PACLITAXEL ALBUMIN 5 mg in 1mL Injection Injection 233 x 100mg Vial PACLITAXEL IN SODIUM CHLORIDE 0.9% 108 mg Intravenous Infusion Intravenous Infusion 750 ml PACLITAXEL IN SODIUM CHLORIDE 0.9% 130 mg Intravenous Infusion Intravenous Infusion 500 ml

5 PACLITAXEL IN SODIUM CHLORIDE 0.9% 138 mg Intravenous Infusion Intravenous Infusion 250 ml PACLITAXEL IN SODIUM CHLORIDE 0.9% 159 mg Intravenous Infusion Intravenous Infusion 750 ml PACLITAXEL IN SODIUM CHLORIDE 0.9% 177 mg Intravenous Infusion Intravenous Infusion 500 ml PACLITAXEL IN SODIUM CHLORIDE 0.9% 180 mg Intravenous Infusion Intravenous Infusion 1 Bag PACLITAXEL IN SODIUM CHLORIDE 0.9% 351 mg Intravenous Infusion Intravenous Infusion 1 Bag PACLITAXEL IN SODIUM CHLORIDE 0.9% 90 mg Intravenous Infusion Intravenous Infusion 250 ml PEMBROLIZUMAB (MK ) COMPASSIONATE SUPPLY 50 mg Injection Injection 750 mg PERTUZUMAB (KAITLIN TRIAL) 30 mg in 1mL Injection Injection 63 Vial PERTUZUMAB (PERUSE TRIAL) 30 mg in 1mL Injection Injection 22 Vial PERTUZUMAB (PHEREXA TRIAL) 30 mg in 1mL Injection Injection 14 Vial PERTUZUMAB / PLACEBO (MARIANNE TRIAL) 420 mg Injection Injection 9 Vial PERTUZUMAB 420 mg Injection solution Injection solution 868 ml PERTUZUMAB IN SODIUM CHLORIDE 0.9% 420 mg Infusion Infusion ml SERVICE CHARGE (HOMECARE) TRASTUZUMAB Service Charge Service Charge 12 Pack SERVICE CHARGE (HOMECARE) TRASTUZUMAB S/C Service Charge Service Charge 287 Pack TRASTUZUMAB (HOMECARE) 1 mg in 1mL Injection Injection 3875 mg TRASTUZUMAB (HOMECARE) 600 mg in 5mL Subcutaneous Injection Subcutaneous Injection 1420 ml TRASTUZUMAB (KAITLIN TRIAL) 150 mg Injection Injection 154 Vial TRASTUZUMAB (KATHERINE TRIAL) 150 mg Injection Injection 83 Vial TRASTUZUMAB (PHEREXA TRIAL) 150 mg Injection Injection 24 Vial TRASTUZUMAB 150 mg Injection Injection 188 Vial TRASTUZUMAB 600 mg in 5mL Subcutaneous Injection Subcutaneous Injection 148 Vial TRASTUZUMAB EMTANSINE (KADCYLA) 100 mg Injection Injection 4300 mg TRASTUZUMAB EMTANSINE (KADCYLA) 160 mg Injection Injection 3680 mg TRASTUZUMAB EMTANSINE (KAITLIN TRIAL) 160 mg Injection Injection 4 Vial TRASTUZUMAB EMTANSINE (KATHERINE TRIAL) 160 mg Injection Injection 16 Vial TRASTUZUMAB IN SODIUM CHLORIDE 0.9% 300 mg Infusion Infusion 3250 ml TRASTUZUMAB IN SODIUM CHLORIDE 0.9% 336 mg Infusion Infusion 1 Bag TRASTUZUMAB IN SODIUM CHLORIDE 0.9% 378 mg Intravenous Infusion Intravenous Infusion 1 Bag TRASTUZUMAB IN SODIUM CHLORIDE 0.9% 390 mg Infusion Infusion 20 Bag TRASTUZUMAB IN SODIUM CHLORIDE 0.9% 450 mg Infusion Infusion 5 Bag TRASTUZUMAB IN SODIUM CHLORIDE 0.9% 483 mg Infusion Infusion 250 ml

6 TRASTUZUMAB IN SODIUM CHLORIDE 0.9% 515 mg Infusion Infusion 8 Bag TRASTUZUMAB IN SODIUM CHLORIDE 0.9% 600 mg Infusion Infusion 1500 ml TRASTUZUMAB MCC DM1 (MARIANNE TRIAL) 160 mg Injection Injection 22 Vial VEMURAFENIB / PLACEBO (BRIM 8 (G027826) TRIAL) 240 mg Tablets Tablets 720 Tablet

7 Prescriptions Issued for Listed Drugs between 01 August 2014 and 31 July 2015 Drug Description Form Total Unit DOCETAXEL (GALAXY-2 TRIAL) 80 mg in 4mL Injection Injection 4 Vial DOCETAXEL 20 mg in 1mL Injection Injection 1089 ml DOCETAXEL IN SODIUM CHLORIDE 0.9% 100 mg Infusion Infusion 21 Bag DOCETAXEL IN SODIUM CHLORIDE 0.9% 110 mg Infusion Infusion 54 Bag DOCETAXEL IN SODIUM CHLORIDE 0.9% 120 mg Infusion Infusion 94 Bag DOCETAXEL IN SODIUM CHLORIDE 0.9% 130 mg Infusion Infusion 96 Bag DOCETAXEL IN SODIUM CHLORIDE 0.9% 140 mg Infusion Infusion 76 Bag DOCETAXEL IN SODIUM CHLORIDE 0.9% 150 mg Infusion Infusion 73 Bag DOCETAXEL IN SODIUM CHLORIDE 0.9% 160 mg Infusion Infusion 27 Bag DOCETAXEL IN SODIUM CHLORIDE 0.9% 170 mg Infusion Infusion 2250 ml DOCETAXEL IN SODIUM CHLORIDE 0.9% 180 mg Infusion Infusion 500 ml DOCETAXEL IN SODIUM CHLORIDE 0.9% 190 mg Infusion Infusion 1750 ml Bag DOCETAXEL IN SODIUM CHLORIDE 0.9% 200 mg Infusion Infusion 1000 ml DOCETAXEL IN SODIUM CHLORIDE 90 mg Intravenous Infusion Intravenous Infusion 500 ml DOCETAXEL INTRAVENOUS INFUSION Unspecified 83 Bag